Cost-effectiveness analysis of rimegepant for on-demand acute treatment of migraine in China
While rimegepant shows clinical efficacy in providing rapid relief from migraine symptoms, its current pricing exceeds the threshold for cost-effectiveness in the Chinese healthcare setting. This study underscores the need for price adjustments to enhance the accessibility and economic viability of new migraine treatments.
Authors
- Shuo Tian (ORCID: https://orcid.org/0009-0004-5839-5129)
- Qiao Liu (ORCID: https://orcid.org/0000-0001-8739-6236)
- Shenglan Tan (ORCID: https://orcid.org/0000-0003-0292-7195)
- Yujin Guo (ORCID: https://orcid.org/0009-0005-2886-4067)
- Jiani Luo
- Yuping Yang (ORCID: https://orcid.org/0000-0002-2226-7676)
- Chuanyu Yang
Institutions
- Central South University (CN)
- Guilin Medical University (CN)
- Tongren Hospital (CN)
- Jining First People's Hospital (CN)
- Zhuzhou Central Hospital (CN)
- Second Xiangya Hospital of Central South University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2024-08-23
- DOI
- https://doi.org/10.3389/fneur.2024.1411576
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00